Accordingly, inhibiting this signaling axis by the use of specific small molecule inhibitors of JAK2 has recently been investigated as a point of therapeutic intervention in multiple human tumor indications [3], [21], [22], [23], [24]. This evidence concerns the gene JAK2 and neoplasm.